David Dornan

Summary

Affiliation: Genentech Inc
Country: USA

Publications

  1. ncbi Statistical techniques to construct assays for identifying likely responders to a treatment under evaluation from cell line genomic data
    Erich P Huang
    Biometric Research Branch Department of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health Rockville, MD 20852, USA
    BMC Cancer 10:586. 2010
  2. ncbi Effect of FCGR2A and FCGR3A variants on CLL outcome
    David Dornan
    Molecular Diagnostics and Cancer Cell Biology, Genentech Inc, South San Francisco, CA, USA
    Blood 116:4212-22. 2010

Collaborators

Detail Information

Publications2

  1. ncbi Statistical techniques to construct assays for identifying likely responders to a treatment under evaluation from cell line genomic data
    Erich P Huang
    Biometric Research Branch Department of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health Rockville, MD 20852, USA
    BMC Cancer 10:586. 2010
    ..In this manuscript, we present a novel approach to developing robust genomic predictors that are not only capable of generalizing from in-vitro to patient, but are also amenable to clinically validated assays such as qRT-PCR...
  2. ncbi Effect of FCGR2A and FCGR3A variants on CLL outcome
    David Dornan
    Molecular Diagnostics and Cancer Cell Biology, Genentech Inc, South San Francisco, CA, USA
    Blood 116:4212-22. 2010
    ..42 CI]; P = .48, respectively). Overall, our results suggest that FCGR2A and FCGR3A polymorphisms do not significantly influence the outcomes of relapsed or refractory CLL patients treated with FC or the monoclonal antibody regimen R-FC...